Products

Type Ⅰ+Ⅲ Live-Attenuated Poliomyelitis Vaccine (Human Diploid Cell)

Product Advantages:

Made from the attenuated strain which has been safely used for about 60 years.
Cultivated in human diploid cells.
Two dosage forms, dragee candy and oral liquid.
10 or 5 doses per pack.

Type Ⅰ+Ⅲ Live-Attenuated Poliomyelitis Vaccine (Human Diploid Cell)
About Products Product Description R & D process Publications Related news

The First Live-Attenuated Poliomyelitis Vaccine in Dragee Candy in China.

In the newly found china, in order to guarantee that the children from remote areas can immunize with poliomyelitis vaccine, scientists in IMBCAMS innovated a unique dosage form of live-attenuated polio vaccine, the dragee candy with improved thermostability. 

With progressive efforts, an independently established human diploid cell line, KMB17, replaced the initially used monkey kidney cells as cell substrates. This change represents a higher quality of our products. 

Main Active Composition:

Type and Type live-attenuated Poliomyelitis viruses.

Description: The dragee candy dosage form should be white ball pill. The oral liquid dosage form should be clear orange liquid.

Storage: Stored in dark place below -20. Cold-chain transportation are required.

Period of Validity: 24 months.

Packaging: Per pack contains 10 doses of dragee candy, or 5 doses of oral liquid.

Indication:

The vaccine can stimulate immune response to prevent poliomyelitis caused by infection of poliovirus type and .

Usage:

Mainly for the children over 2 months age.

Administration and Dosage:

The primary series of the vaccine consists of three doses administered orally, preferably 4 to 6 weeks apart and usually started from 2 months age. A booster dose should be administered at 4 years old. 1 pill of dragee candy or 2 drops of oral liquid per person per time.

Either, the vaccine can be used following the national immunization program.

The people in other age groups can use if necessary. 

 

    Coming Soon...